Daiichi Sankyo Reports 16.6% Revenue Growth in First Three Quarters of FY2024
Japan-based Daiichi Sankyo (TYO: 4568) has reported revenues of JPY 1.37 trillion ($8.927 billion) for...
ADC / XDC
MediLink Therapeutics’ YL217 Receives FDA IND Clearance for Novel ADC Targeting Gastrointestinal Cancers
MediLink Therapeutics, a clinical-stage biotech company, announced today that its internally developed antibody-drug conjugate (ADC),...
GeneQuantum Secures $13 Billion Deals with Biohaven and AimedBio for ADC Development
Suzhou based biotech firm GeneQuantum has announced a series of major commercial cooperation pacts worth...
Zai Lab’s ZL-1310 Granted Orphan Drug Designation by FDA for SCLC
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced that the US Food...
Lepu Biopharma Licenses Potential Best-in-Class ADC MRG007 to ArriVent
Lepu Biopharma Co., Ltd (HKG: 2157) has announced an exclusive licensing agreement with ArriVent BioPharma,...
MediLink’s YL201 Receives Breakthrough Therapy Designation for Nasopharyngeal Carcinoma
Suzhou-based biotech MediLink Therapeutics (Suzhou) Co., Ltd has announced receiving another breakthrough therapy designation (BTD)...
FDA Approves Datroway for HR+/HER2- Breast Cancer Treatment
Datroway (datopotamab deruxtecan-dlnk, Dato-Dxd), a Trop-2-directed antibody and topoisomerase inhibitor conjugate co-developed by Japan-based Daiichi...
Daiichi Sankyo Acquires Gatipotuzumab IP Rights for $132.5M
Japan-based Daiichi Sankyo Company, Ltd (TYO: 4568) has announced an investment of USD 132.5 million...
Hengrui’s HER2-Targeted ADC and Antibody Drug Combo Approved for Trials
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving clinical trial approval from...
CSPC’s SYS 6043 Receives FDA Approval for Clinical Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its in-house developed SYS 6043...
Innovent’s IBI343 Receives Breakthrough Therapy Designation for Pancreatic Cancer
China-based biopharma Innovent Biologics, Inc. (HKG: 1801) has announced receiving another Breakthrough Therapy Designation (BTD)...
MediLink Therapeutics and AstraZeneca Collaborate on YL201 and Imfinzi Combo for Solid Tumors
Suzhou-based biotech company MediLink Therapeutics (Suzhou) Co., Ltd has announced a clinical cooperation agreement with...
3SBio Acquires Licensing Rights to Duality Biologics’ HER2-Targeting ADC DB-1303
China-based 3SBio Inc. (HKG: 1530) has entered into a strategic partnership with Duality Biologics, a...
CSPC Pharmaceutical’s ADC Pipeline Advances with SYS 6041 Approval
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has reported significant progress in its antibody...
Henlius Biotech Gains NMPA Clearance for HLX43 ADC Study
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that it has received clearance from...
Doma Biopharma Receives FDA Clearance for DM002 Phase I Study-Fineline Info & Tech
China-based Doma Biopharmaceutical (Suzhou) Co., Ltd has announced that it has received clearance from the...
Biocytogen and SOTIO Biotech Partner on Colorectal Cancer ADC Candidate SOT109
China-based Biocytogen (HKG: 2315) has announced an option and licensing agreement with SOTIO Biotech, allowing...
Boehringer Ingelheim Licenses ADC Technology from Synaffix to Boost Portfolio
German giant Boehringer Ingelheim has announced the licensing of antibody drug conjugate (ADC) technology from...
MediLink and Zai Lab Collaborate on LRRC15-Targeted ADC Drug ZL-6201
Chinese biotechs MediLink Therapeutics (Suzhou) Co., Ltd and Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688)...
Astellas’ Padcev and Keytruda Combo Cleared by NMPA for Urothelial Cancer
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced marketing clearance by China’s National Medical Products...